

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/IM/BSE/2021-22

Date: December 04, 2021

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla complex
Bandra(E) Mumbai- 400051

Company No: 531146

Sub: Disclosure under Regulation 30 read with para A of Schedule III and Regulations 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Ma'am,

Pursuant to the applicable provisions of the Regulation, attached herewith Investor presentation

This is for your information and records.

Thanking You

Yours truly,
For Medicamen Biotech Limited


Parul Choudhary
Company Secretary & Compliance Officer
ACS: 44157






Agrochemicals



Pharmaceuticals



Speciality Chemicals & Intermediates

Shivalik Rasayan Ltd

CORPORATE PRESENTATION

Vision

“Improving health through offering innovative products”
by leveraging R&D expertise in following three verticals:

- o Agro Chemicals
- o Pharmaceuticals
- o Speciality Chemicals




Contents



**Corporate
Overview**





Portfolio & Pipeline



**R&D and
Manufacturing**



**Strategy
& Plans**



Who are we??

Shivalik Rasayan Ltd (SRL) is a leading producer of Agrochemicals in India with a market cap of > \$ 150 million and has recently expanded into Pharmaceuticals & Speciality Chemicals by investing > \$ 40 million

Leadership team of SRL has been accredited with successful turn around of sick & financially overburdened companies (Shivalik Rasayan & Medicamen Biotech)

SRL has a team of business & technical professionals with expertise to setup & run complex chemical & dosage form manufacturing plants

SRL, through its investments in R&D and manufacturing, has its products presently available in more than 30 countries

Business Overview

R&D Capabilities:

Chemical & Formulation Development, Analytical Research

Manufacturing Capabilities:


Agro-chemicals, Speciality Chemicals, APIs, Dosage Forms

Dosage Forms:

Injectables (RTU & Lyo Vials, PFS), Syrups, Ointments, Oral solids (Capsules, Tablets, Dry Syrups)

Additional Services:


CDO, CMO & CRAMS




API = Active Pharmaceutical Ingredient, FDF = Finished Dosage Form, CDO = Contract Development Organization, CMO = Contract Manufacturing Organization, CRAMS = Contract Research And Manufacturing Services

Group Structure

Shareholding as of June 30, 2021



Milestones



Road Ahead

- Targeted API facility approvals by USFDA, EMEA
- Start of new Agro- & Speciality Chemical Plant, Dahej



- Targeted oncology FDF launch in India
- Targeted start of FDF dossier filing in USA & Europe
- Targeted FDF (onco) facility approval by USFDA, EMEA
- Targeted first marketing authorizations in USA & Europe
- Targeted first launches in USA, Europe

Our Leadership Team

The Executive Management team at SRL has an extensive global experience & subject matter expertise and is passionate about fulfilling the vision of the company



Rahul Bishnoi
Chairman



Vimal Kumar Shrawat, PhD
Managing Director



Suresh Kumar Singh
Vice-Chairman



Akshay Kant Chaturvedi, PhD
Executive Director
R&D



Rajesh Madan
CEO
MBL



Anand Kumar
Vice President
Sales & BD



Subir Chopra
Vice President
India & South Asia

SRL Group Strengths At A Glance

> 500

Employees

Scientists : 60
QA & QC : 150
Pharmacists : 100



1

Dimethoate Technical
(& # 2 Malathion
Technical)
producer in India



> 75

Product approvals in
overseas markets*



> 30

Regulatory Agency
Approvals (including
WHO, Brazil)*



>10

**Non-Oncology
products*** in pipeline
for EU and Australia



> 25

Oncology products
(APIs & Dosage Forms)
in portfolio & pipeline



6

Manufacturing sites
(Agrochemicals, Specialty
Chemicals, APIs, Dosage
Forms)



* Dosage Forms

SRL Group Global Presence

Agrochemicals

- Products available in India and key overseas markets

Dosage Forms: non-oncology

- Our products are approved in more than 30 countries and are supplied through a network of alliance partners and distributors

Dosage Forms: oncology

- Presently in launch phase in India
- Global roll out planned starting 2022

APIs: oncology & non-oncology

- Presently in plant validation & regulatory phases
- Will be available for commercial sales in early 2023




Contents



**Corporate
Overview**



Portfolio & Pipeline



**R&D and
Manufacturing**



**Strategy
& Plans**



SRL Group Portfolio At A Glance



Agrochemicals

2

Products for which
SRL is largest Indian
manufacturer

Specialization in organophosphorus
based insecticides & chemicals

> 20

Products under
development

APIs

> 25

Non-Oncology
APIs

> 35

Oncology
APIs



> 75

Non-Oncology
Orals, Liquids, Ointments

> 25

Oncology
Orals & Injectables

Agrochemicals

Insecticides

Malathion Technical
Dimethoate Technical
Dinotefuran Technical
Cyantraniliprole Technical
Fipronil Technical
Pymetrozine Technical
Chlorantraniprole Technical

Fungicides

Prothioconazole Technical
Azoxistrobin Technical
Hexaconazole Technical

Intermediates / Specialty Chemicals

t – Oxirane
PG easter for Kresoxim-methyl
1,2,4-Triazole



Oncology APIs & Dosage Forms

Product selection criteria:

* attractive market size * patent expiry launches * low competition

S No	Product	API by SRL	Global Revenues*
1	Abiraterone	Planned	\$ 3.2 b
2	Bortezomib	Available	\$ 1.5 b
3	Dasatinib	Planned	\$ 2.3 b
4	Ibrutinib	Planned	\$ 5.8 b
5	Lenalidomide	Planned	\$ 5.7 b
6	Nilotinib	Planned	\$ 1.6 b
7	Palbociclib	Planned	\$ 5.7 b
8	Pemetrexed	Planned	\$ 2.5 b

S No	Product	API by SRL	Global Revenues*
1	Carfilzomib	Planned	\$ 1.1 b
2	Cabozantinib	Planned	\$ 1.0 b
3	Lenvatinib	Planned	\$ 0.6 b
4	Acalabrutinib	Planned	\$ 0.2 b
5	Pazopanib	Planned	\$ 0.6 b
6	Capecitabine	Available	\$ 0.7 b
7	Azacitidine	Available	\$ 0.7 b
8	Bendamustine	Available	\$ 0.7 b

* IQVIA, MAT Q1-2020
 Note Products protected by valid patents (of innovators / third parties) are not offered for commercialization / sale in countries where the sale of such products constitutes a patent infringement





Non-Oncology APIs

Well thought after product strategy:

- Products with attractive global revenues (> \$ 1b)
- Substantial expected revenues for SRL

Development Completed

#	API	Global Revenues*
1	Dimethyl Fumarate	\$ 4.9 b
2	Fingolimod	\$ 3.7 b
3	Pirfenidone	\$ 1.3 b

Under Development (>20 APIs)

#	API
1	Saxagliptin
2	Sitagliptin Phosphate
3	Vildagliptin

#	API
4	Monomethyl Fumarate
5	Acebrophylline
6	Sofosbuvir

* IQVIA, MAT Q1-2020
Note Products protected by valid patents (of innovators / third parties) are not offered for commercialization / sale in countries where the sale of such products constitutes a patent infringement


Contents



**Corporate
Overview**



Portfolio & Pipeline




**R&D and
Manufacturing**



**Strategy
& Plans**

R&D and Manufacturing At A Glance



R&D Center *Bhiwadi*



R&D Center *Bhiwadi*

- Highly experienced technical team (60 scientists & pharmacists) with multiple developments and patents to its credit
- 12,000 sq ft premises with investment > Rs 30 crores
- Equipped with best-in-class equipment and systems for development of technical, complex APIs & formulations
- Full in-house capabilities for analytical research, stability studies, process validation and improvements
- A robust quality assurance system for product development
- Para IV filing capability with different API polymorphs
- Strong in-house intellectual property management skills and expertise
- Demonstrated technology transfer capabilities and operating systems
- Approved by DSIR (Department of Scientific & Industrial Research), Govt of India




Agrochemicals Plant *Dehradun*

- 1450 MT annual capacity
- > 95% capacity utilization
- 20 acres land with green surroundings



Agro & Speciality Chemicals Plant Dahej

- New greenfield plant in GIDC, Dahej, Gujarat
- 50,000 m² facility
- Environmental clearance received from Ministry of Environment & Forests
- Initially only one block planned for Insecticides & Fungicides:
 - Planned annual capacity: 3500 MT
- Operation commencement expected in Jan 2023



API Plant Dahej



API Plant *Dahej*

- Site area of 50,000 m² including all production blocks, buildings, utilities*
- Design compliant with best-in-class regulatory requirements (US, Europe, Japan)
- 4 oncology & 4 non-oncology blocks planned: thereof 1 onco & 1 non-onco block presently operational
- Robust GMP compliant containment facility to rule out cross contamination between onco & non-onco APIs
 - Extensive use of Active & Passive valves at various stages of process to achieve full containment
 - Containment compliance starting from active raw material & API sampling to dispensing
- Tested & validated technology transfer capabilities from R&D center to production floor
- Fully equipped in-house quality control laboratory for chemical & microbiological testing
- On-site regulatory affairs department experienced in approval requirements of all major geographies



Non-Onco Dosage Form Plant *Bhiwadi*

- cGMP compliant facility with 210,000 sq ft covered area
- Product types: Tablets, Capsules, Dry Syrups, Liquid Orals, ORS
- Separate sections:
 - Beta Lactam Orals
 - Non-Beta Lactam Orals
 - Iron & Folic Acid Orals
 - Liquid Orals



Non-Onco Dosage Form Plant *Unit-1, Haridwar*

- cGMP compliant facility with 32,000 sq ft covered area
- Product types: Tablets, Ointments, Liquid Orals



Oncology FDF Plant

Unit-2, Haridwar

Oncology FDF Plant


Unit-2: Haridwar

Injectable Section:


- Capacity of 120 vials/min with flexibility of handling different vial sizes, integrated with Particle Monitoring System for non-viable particle counting (NVPC)
- 5.6 m² with 6+1 radiant shelves Lyophilization Unit from LSI having self-stoppering facility
- Unit Preparation & Sterilization: A double-door autoclave, SCADA (Supervisory Control and Data Acquisition) operated 10 litre & 50 litre capacity for manufacturing or holding vessel with filtration skid installed in between LAF/DPB units to maintain sterility of the products
- A dedicated MLAF Unit for lyophilizer loading and unloading



Lyophilizer Unit



SCADA: Sterile
Manufacturing
Integrated Vial Filling Line



Confidential



Integrated Line



Tablet Compression in Isolator



FBD

Oncology FDF Plant *Unit-2: Haridwar*

Oral Solid Dose (OSD) Section:

- Integrated Granulation line (Glatt , 30 Kg capacity) with WIP technology & interchangeable bowl size
- Tablet compression & encapsulation with Isolators
- Tablet coater with WIP technology (Glatt)
- Blister packing machine for Alu-Alu & Alu-PVC packing
- Bottle packing line in progress.



Blister Packaging


Contents



**Corporate
Overview**



Portfolio & Pipeline



**R&D and
Manufacturing**



**Strategy
& Plans**



Development & Commercial Strategy

- **Development Plan:** pegged on patent expiry launches for Technicals as well Pharmaceuticals wherever applicable
- **Portfolio Strategy:** focused on (1) patent expiry launches, (2) difficult to produce products with low competition, (3) high value & low volume products
- **API Strategy:** (1) backward integration of APIs for dosage forms, (2) APIs also offered in mature markets (US, Europe, Japan) for third party sales
- **Manufacturing Strategy:** manufacturing capacity for Technicals, KSMs, APIs & dosage forms available for both captive consumption as well as CMO services
- **Geographical Roll Out:**
 - Agrochemicals focused on India and selected overseas markets
 - Pharmaceuticals focused on US, Europe, Australia and all major markets in Asia, Africa, LAM
- **Commercialization Plan:**
 - Agrochemicals: continue maximization of revenues to existing & overseas formulators through India based team and a network of distributors
 - Pharmaceuticals: (1) own team and setup in India and few select countries, (2) product launches through leading alliance partners in most countries

Contact Details

Global Head Quarters:

1506 Chiranjiv Tower, 43 Nehru Place, New Delhi – 110019, India

info@shivalikrasayan.com +91 11 47589500

Websites:

www.shivalikrasayan.com

www.medicamen.com

Disclaimer: Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, cash flow projections, our exposure to market risks as well as other risks. Shivalik Rasayan Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.